Glenmark Pharmaceuticals Ltd Q1 FY27 Earnings Call: Reaffirms 21-22% Margin Guidance, Oncology Brands Target $500-600 Mn

Glenmark Pharmaceuticals Ltd held its Q1 FY27 earnings call on July 31, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Broad-Based Growth Across All Regions

• Consolidated revenue of Rs.40,185 Mn in Q1 FY 2026-2027, up 23.1% YoY from Rs.32,644 Mn in Q1 FY 2025-2026, with base business growth exceeding 18% excluding deferred income.
• India formulation revenue of Rs.14,321 Mn (+15.5% YoY), with secondary sales growth of 18.1% in Q1 and 14.3% as per MAT June 2026, outperforming IPM growth of 12.2% and 10% respectively.
• North America revenue of Rs.10,974 Mn (+41.1% YoY), with core business (ex-out-licensing income) growing 19.8% YoY, driven by respiratory launches.
• Europe operations revenue of Rs.7,472 Mn (+11.9% YoY), with management noting the region was "muted due to transformation to branded respiratory and dermatology."
• Emerging markets revenue of Rs.7,304 Mn (+27.7% YoY), the fastest-growing region in percentage terms.
• Consumer care (GCC) primary sales of Rs.1,558 Mn (+28% YoY), with flagship brand Candid growing over 30%.

India Strength, US Recovery, Europe in Transition

• India business ranked 13th with 2.37% market share (IQVIA MAT June 2026), ranked 2nd in dermatology, 3rd in respiratory, and 4th in cardiac; management guided 12-15% consistent growth from FY 2026-2027 onward, driven by volume growth of 6-7%, new product contribution of 3%, and value growth of 3-4%.
• India MR strength stood at approximately 5,600 as of Q1 FY 2026-2027, with annual additions of 300-400 MRs; no major oncology expansion required as existing sales force covers it.
• North America core business grew 19.8% YoY (ex-out-licensing), with management expecting growth to sustain over the next few quarters; 9 products launched in Q1 and CGT designation received for Fluticasone Propionate 44 mcg (generic to Flovent HFA) with 180-day exclusivity upon commercialization.
• Europe business guided at high single-digit growth for FY 2026-2027, with a return to double-digit growth in FY 2027-2028 driven by branded respiratory and derm launches; branded products currently contribute ~30% of Europe revenue, with management targeting ~60% over the next 5 years.
• Emerging markets grew 27.7% YoY, with management noting the region as "very strong" during the quarter.

Oncology, Respiratory, and Specialty Assets Advancing

• ISB 2001 (multi-specific antibody) — over 160 subjects dosed; phase 1/2 combination study initiated; management identified it as a candidate to become Glenmark's next large global specialty brand following Win-Levy.
• Trastuzumab deruxtecan (HER2-targeting ADC) — first wave of MA applications expected in Q2 FY 2026-2027; phase 3 trial in PROC initiated in India.
• Omalizumab (EGFR TKI) — MA applications filed in 13 countries as of June 2026; first commercial launch anticipated in H2 FY 2026-2027.
• Ryaltris (EGFR inhibitor) — MA applications in 24 countries; first commercial launch expected in FY 2027-2028.
• Amlotinib (non-small cell lung cancer) launch expected by end of FY 2026-2027, followed by Trastuzumab and Envafolimab; management expects these three oncology brands to generate $500-600 Mn in revenue over a 5-6 year timeframe, leveraging the same infrastructure for future ISB 2001 launch.
• At least two of three respiratory products (110 MCG, fluticasone nasal spray, ipratropium) anticipated to receive approval in H2 FY 2026-2027; already-launched product 44 will see a full quarter benefit in Q2 FY 2026-2027.
• Win-Levy adoption in Europe has "only just begun"; management plans to promote additional branded derm products alongside it to build the European derm franchise; Ryltris commercialized in 57 markets with global secondary sales growth >40% YoY.

21-22% Margin Guidance Reaffirmed Amid Geopolitical Headwinds

• FY 2026-2027 operating margin guidance of 21-22% reaffirmed by management, with expectations that mitigation strategies — improved product mix, geographic mix, new US respiratory launches, and strong India growth — will offset cost headwinds.
• Geopolitical situation impacting gross margins through higher API and logistics costs, with pressure expected to persist for at least Q2 FY 2026-2027 and Q3 FY 2026-2027; management estimated a potential 1-2% margin impact if the elevated cost environment continues.
• R&D spend of Rs.289 Cr in Q1 FY 2026-2027, with management reiterating guidance of 7-8% of revenue going forward; IGI (2301) clinical trial investments over the next 2-3 years are included in the previously guided $70 Mn spend.
• Operating margins were impacted by reinvestments in the base business, innovative business expansions, and higher logistics costs; gross interest costs increased due to higher lease expenses and bank commitment charges.
• Working capital initiatives generated incremental income through interest rate arbitrage, reflected in other income; management committed to maintaining a gross debt zero position on the balance sheet.

Zero Gross Debt, AbbVie Upfront Received, Working Capital in Focus

• $700 Mn upfront from the AbbVie deal received as of Q1 FY 2026-2027; no milestone payments from the remaining $1.2 Bn have been activated yet; the deferred income from the IGI deal was confirmed to be part of the $700 Mn upfront payment.
• Gross debt maintained at zero as of Q1 FY 2026-2027, with operating cash of approximately Rs.800-900 Cr; cash position fluctuates due to trade-related spending.
• Net working capital days of 115 days as of Q1 FY 2026-2027, with management reaffirming full-year FY 2026-2027 guidance at this level; current quarter below the 115-day threshold.
• US litigation provisions largely taken in Q4 FY 2025-2026, including settlements with state AGs and DPPs; remaining groups (EPPs and one more) are expected but incremental P&L impact is not significant; cash outflows will occur over FY 2026-2027 and FY 2027-2028, as provisions were booked conservatively upfront.
• CFO outlined initiatives to improve working capital efficiency: reducing debtor days, improving payment terms, and optimizing supply chain financing, MSME financing, global factoring, and packing credit to free up cash for future growth (FY 2027-2028 and beyond).

Near-Term Execution Anchored on Respiratory and Oncology Launches

• Top execution priorities for FY 2026-2027: preparing for US respiratory launches in H2, launching Anlotinib in India and emerging markets in H2 followed by Trastuzumab, with accompanying field force expansions in India and emerging markets.
• Management views growth risk as relatively low for FY 2026-2027, with current growth driven by prior launches; the shift to branded and unique products reduces regulatory risk.
• US injectables (20+ products, including partner projects) are not yet meaningful; primary FY 2026-2027 drivers are respiratory launches (fluticasone 44, fluticasone nasal spray OTC, and 2-3 more in H2); differentiated injectables (Montero) are expected to contribute from FY 2027-2028.
• New launches Teva and Bukenza generated over Rs.100 Cr in sales in the first 12 months post-launch; Brokensa brand first-year revenue reached Rs.100 Cr; chronic respiratory product GFB first-year revenue was approximately Rs.70-80 Cr; Semaglutide brand annualized sales of Rs.20-25 Cr is helping reverse diabetes business decline.
• Over a 5- to 10-year horizon, management expects "significant innovation launches to materialise" across respiratory and oncology franchises, with the IGI pipeline (assets 2301 and 2302) progressing; for ISB 2301 (pentaspecific antibody), management will wait for clinical data and proof-of-concept before pursuing a partnering deal.
• No visibility on Biocrest's further development of ISB 813 after its Astra acquisition; a backup compound (star 310) has completed phase one.